A Prospective Randomized Controlled Multicenter Clinical Trial Comparing Paste-Type Acellular Dermal Matrix to Standard Care for the Treatment of Chronic Wounds.
Youn Hwan KimHyung Sup ShimJihye LeeSang Wha KimPublished in: Journal of clinical medicine (2022)
The treatment of chronic wounds remains challenging. Acellular dermal matrix (ADM) has been shown to be effective for various types of wound healing. This study was designed to compare the wound size reduction rate after 12 weeks between patients receiving paste-type ADM and standard wound care. Patients over 19 years old with chronic wounds, deeper than full-thickness skin defects, more than 4 cm 2 in size that did not heal over the 3 weeks before the study were included. After a screening period of 7 days, patients were randomized to receive either paste-type ADM or standard wound care. The wound status was evaluated at baseline, 1, 2, 4, 8, and 12 weeks. A total of 86 patients were enrolled in this study. The wounds continuously and constantly reduced in size from week 1, and the reduction rate was significantly greater in the study group from week 2 until the end (week 12). In the study group, wound healing was achieved in 29 of 38 wounds (76.3%). Paste-type ADM might be a useful option for wound healing and can be applied safely and efficiently for advanced wound care.
Keyphrases
- wound healing
- clinical trial
- healthcare
- end stage renal disease
- palliative care
- ejection fraction
- newly diagnosed
- randomized controlled trial
- prognostic factors
- double blind
- quality improvement
- open label
- cross sectional
- placebo controlled
- patient reported outcomes
- study protocol
- surgical site infection
- high resolution
- replacement therapy